AstraZeneca invests in Imperial's self-amplifying RNA technology with eye on future drugs
September 23, 2021 at 03:17 AM EDT
AstraZeneca has struck a deal with the firm behind Imperial College London's experimental Covid-19 vaccine.
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart Quotes delayed at least 20 minutes. By accessing this page, you agree to the following Privacy Policy and Terms and Conditions. |
|